3-(2-fluorophenyl)-2-methylquinazolin-4(3H)-one | 1897-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(2-fluorophenyl)-2-methylquinazolin-4(3H)-one
• 英文别名: 3-(2-Fluorophenyl)-2-methylquinazolin-4-one
• CAS: 1897-87-6
• 化学式: C₁₅H₁₁FN₂O
• 分子量: 254.264
• InChiKey: GSTFOVILIDDZER-UHFFFAOYSA-N

物化性质

• 熔点：
  116-117 °C
• 沸点：
  392.7±44.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(2-Fluorophenyl)-2-methylquinazolin-4-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(2-Fluorophenyl)-2-methylquinazolin-4-one
CAS number: 1897-87-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H11FN2O
Molecular weight: 254.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(2-fluorophenyl)-2-methylquinazolin-4(3H)-one 在 劳森试剂 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 3.0h， 以95%的产率得到3-(2-fluorophenyl)-2-methylquinazoline-4(3H)-thione
  参考文献：
  名称：

  在外消旋和光学纯 NC 轴向手性 3-(2-卤代苯基)喹唑啉-4-硫酮衍生物中检测到分子间卤素键

  摘要：

  卤素键已被广泛用作各种研究领域的重要超分子工具。然而，关于与分子手性相关的卤素键合的研究相对较少。由于围绕 NC 单键的旋转限制，3-(2-Halophenyl)quinazoline-4-thione 衍生物具有稳定的阻转异构结构。在外消旋和光学纯的NC轴向手性喹唑啉-4-硫酮的X射线单晶结构中，我们发现形成了不同类型的分子间卤素键（C=S⋯X）。也就是说，在外消旋晶体中，邻位之间的分子间卤素键发现-卤素原子和硫原子以周向构象朝向硫代羰基平面取向，导致间规锯齿形阵列。另一方面，对映体纯晶体中的卤素键垂直于硫代羰基平面，导致形成纯手性二聚体。这些结果表明，手性分子中相应的外消旋和光学纯形式有望分别表现出不同的卤素键合性质，应作为不同的化学实体单独研究。

  DOI：

  10.3390/molecules27072369
• 作为产物：
  描述：

  2-氟苯胺 、 邻乙酰氨基苯甲酸 在 三氯化磷 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以71%的产率得到3-(2-fluorophenyl)-2-methylquinazolin-4(3H)-one
  参考文献：
  名称：

  一些新的2-取代的3-芳基-4（3H）-喹唑啉酮类化合物的合成和抗惊厥活性。

  摘要：

  合成了一系列在结构上与2-甲基-3-邻甲苯基-4（3H）-喹唑啉酮（甲喹酮，3）有关的4（3H）-喹唑啉酮并评估了其抗惊厥活性。对这些化合物的初步筛选显示2- [2-氧代-2-（4-吡啶基）乙基] -3-芳基-4（3H）-喹唑啉酮6l和8i，8k和8p-r在其上具有单个邻位取代基3-芳基具有最有前途的抗惊厥活性。分别具有3-邻甲苯基和3-邻氯苯基的化合物6l和8i显示出对MES和scMet诱导的癫痫发作的良好保护，并且在小鼠腹膜内给药后具有相对较低的神经毒性。在确定平均催眠剂量（HD50）和中位致死剂量（LD50）的测试中，它们还显示出低毒性。尽管这些化合物在小鼠和大鼠中口服给药时作为抗惊厥药的作用明显更强，但它们对神经毒性也更大。这种神经毒性在大鼠口服试验中尤为严重，导致边缘保护指数降低。在药物分化试验中，化合物6l对比库林，皮毒素和士的宁诱导的癫痫发作无效，而8i对皮毒素诱导的癫痫发作具有一定的保护作用。

  DOI：

  10.1021/jm00163a027

文献信息

• Palladium-catalyzed four-component carbonylative synthesis of 2,3-disubstituted quinazolin-4(3H)-ones: Convenient methaqualone preparation
  作者：Jin-Bao Peng、Hui-Qing Geng、Wei Wang、Xinxin Qi、Jun Ying、Xiao-Feng Wu

  DOI：10.1016/j.jcat.2018.06.007

  日期：2018.9

  A palladium-catalyzed four-component carbonylative cyclization reaction for the synthesis of 2,3-disubstituted quinazolin-4(3H)-ones has been developed. A range of different 2,3-disubstituted quinazolin-4(3H)-one derivatives were prepared in moderate to good yields employing simple and readily accessible 2-iodoanilines, nitro compounds and acid anhydrides as the synthetic precursors. Mo(CO)6 acted

  已经开发了钯催化的四组分羰基环化反应，用于合成2,3-二取代的喹唑啉-4（3H）-one。使用简单且易于获得的2-碘苯胺，硝基化合物和酸酐作为合成前体，以中等至良好的产率制备了一系列不同的2,3-二取代的喹唑啉-4（3H）-one衍生物。Mo（CO）6既充当固体CO源又充当还原剂。值得注意的是，在我们的条件下，甲喹酮作为镇静剂和催眠药也可以很容易地制备，收率为68％（4b）。
• Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-quinazolinones
  作者：James F. Wolfe、Terry L. Rathman、Mark C. Sleevi、James A. Campbell、Thomas D. Greenwood

  DOI：10.1021/jm00163a027

  日期：1990.1

  series of 4(3H)-quinazolinones structurally related to 2-methyl-3-o-tolyl-4(3H)-quinazolinone (methaqualone, 3) were synthesized and evaluated for anticonvulsant activity. Preliminary screening of these compounds revealed that 2-[2-oxo-2-(4-pyridyl)ethyl]-3-aryl-4(3H)-quinazolinones 6l and 8i, 8k, and 8p-r having a single ortho substituent on the 3-aryl group had the most promising anticonvulsant activity

  合成了一系列在结构上与2-甲基-3-邻甲苯基-4（3H）-喹唑啉酮（甲喹酮，3）有关的4（3H）-喹唑啉酮并评估了其抗惊厥活性。对这些化合物的初步筛选显示2- [2-氧代-2-（4-吡啶基）乙基] -3-芳基-4（3H）-喹唑啉酮6l和8i，8k和8p-r在其上具有单个邻位取代基3-芳基具有最有前途的抗惊厥活性。分别具有3-邻甲苯基和3-邻氯苯基的化合物6l和8i显示出对MES和scMet诱导的癫痫发作的良好保护，并且在小鼠腹膜内给药后具有相对较低的神经毒性。在确定平均催眠剂量（HD50）和中位致死剂量（LD50）的测试中，它们还显示出低毒性。尽管这些化合物在小鼠和大鼠中口服给药时作为抗惊厥药的作用明显更强，但它们对神经毒性也更大。这种神经毒性在大鼠口服试验中尤为严重，导致边缘保护指数降低。在药物分化试验中，化合物6l对比库林，皮毒素和士的宁诱导的癫痫发作无效，而8i对皮毒素诱导的癫痫发作具有一定的保护作用。
• REINVESTIGATION OF THE SYNTHESIS OF 2-BENZYL-3-ARYL-QUINAZOLIN-4-[3<i>H</i>]-ONES. AN IMPROVED MULTI-COMPONENT PROCEDURE USING MICROWAVES
  作者：Anshu Dandia、Ruby Singh、Pritima Sarawgi

  DOI：10.1080/00304940509354972

  日期：2005.8

  antifungal a c t i ~ i t y . ~ J ~ An earlier reported conventional synthesis of 2,3-disubstituted quinazolin-4(3H)-ones (4) involves two steps,' I cyclodehydration of 2-benzamidobenzoic acid (1) with excess acetic anhydride under anhydrous conditions to give benzoxazin-4-one (2) followed by reflux of 2 with amines in glacial acetic acid or pyridine.12 The products were obtained in moderate yields and

  4[3H]-喹唑啉酮具有广泛的生物活性1,2，并已被用作具有抗炎、镇痛和催眠作用的抗惊厥药物^。^-^ 一些 4[3H] 喹唑啉酮还显示出中枢神经系统、抗真菌作用，抗菌和抗微生物活性6。8 2,3-二取代喹唑酮与抗病毒、抗菌和抗真菌活性有关。~ J ~ 早先报道的 2,3-二取代喹唑啉-4(3H)-酮 (4) 的常规合成包括两个步骤，'I 2-苯甲酰氨基苯甲酸 (1) 在无水条件下用过量乙酸酐环脱水得到苯并恶嗪-4-一 (2)，然后 2 与胺在冰醋酸或吡啶中回流。12 以中等产率获得产物，反应需要回流 10-12 小时。鉴于我们希望合成一系列具有药效基团的 2,3-二取代喹唑酮 (4) 并在喹唑酮中建立构效关系，我们研究了苯并恶嗪-4-one 与取代苯胺的缩合。与 Mishra 等人早先的报告相反，mand p-取代苯胺得到预期产物 4，o-取代苯胺得到中间体 o-酰基氨基苯甲酰胺 (3)。”
• Atropisomeric quinazolin-4-one derivatives are potent noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists
  作者：W.M Welch、F.E Ewing、J Huang、F.S Menniti、M.J Pagnozzi、K Kelly、P.A Seymour、V Guanowsky、S Guhan、M.R Guinn、D Critchett、J Lazzaro、A.H Ganong、K.M DeVries、T.L Staigers、B.L Chenard

  DOI：10.1016/s0960-894x(00)00622-3

  日期：2001.1

  Piriqualone (1) was found to be an antagonist of AMPA receptors. Structure activity optimization was conducted on each of the three rings in 1 to afford a series of potent and selective antagonists. The sterically crowded environment surrounding the N-3 aryl group provided sufficient thermal stability for atropisomers to be isolated. Separation of these atropisomers resulted in the identification of

  Piriqualone（1）被发现是AMPA受体的拮抗剂。对三个环中的每一个进行结构活性优化，以提供一系列有效和选择性的拮抗剂。N-3芳基周围的空间拥挤环境为要分离的阻转异构体提供了足够的热稳定性。这些阻转异构体的分离导致鉴定出（+）-38（CP-465,022），该化合物以高亲和力（IC50 = 36 nM）与AMPA受体结合并显示出有效的抗惊厥活性。
• SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20150087663A1

  公开（公告）日：2015-03-26

  The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not limited to leukemias and solid tumors, in mammals, especially humans.

  本发明涉及新的氨基嘧啶衍生物的制备和使用，作为自由形式或药学上可接受的盐形式和制剂，用于调节PI3K酶活性介导的紊乱或疾病。本发明还提供包含这些化合物的药学上可接受的组成物和使用这些组成物治疗哺乳动物，特别是人类中PI3K酶在白细胞功能中发挥作用的免疫和炎症紊乱以及与PI3K活性相关的过度增殖性疾病，包括但不限于白血病和实体瘤的方法。